{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:08:51Z","timestamp":1784297331839,"version":"3.55.0"},"reference-count":14,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100020167","name":"Gordon and Llura Gund Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000980","name":"Arthritis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR 070253"],"award-info":[{"award-number":["P30 AR 070253"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR072577"],"award-info":[{"award-number":["P30 AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR077607"],"award-info":[{"award-number":["R01 AR077607"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR080659"],"award-info":[{"award-number":["R01 AR080659"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL155522"],"award-info":[{"award-number":["R01 HL155522"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007273","name":"Weill Cornell Medical College","doi-asserted-by":"publisher","award":["UL1 TR 002384"],"award-info":[{"award-number":["UL1 TR 002384"]}],"id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to present effectiveness and tolerability of apremilast in a cohort of 21 patients with immune checkpoint inhibitor psoriatic arthritis (ICI\u2010PsA) and\/or immune checkpoint inhibitor psoriasis (ICI\u2010PsO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter study combined data from patients treated with apremilast after experiencing ICI\u2010PsO and\/or ICI\u2010PsA. Patients taking apremilast before ICI initiation and patients with preexisting autoimmune disease before ICI therapy were also included. Response to apremilast was determined as complete, partial, or none as determined by improvement in Common Terminology Criteria for Adverse Events grading after drug initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 21 patients who used apremilast for either ICI\u2010PsO and\/or ICI\u2010PsA, but only five of these patients had de novo ICI\u2010PsO and\/or ICI\u2010PsA. Of these five patients, four had partial response or improvement in their immune\u2010related adverse event with apremilast, although there were intolerances in three of these patients. Of the 21 total patients, 16 had a relevant preexisting autoimmune disease, indicating a likely flare of the underlying disease with ICI therapy. Flares occurred much sooner for patients with ICI\u2010PsA (4 weeks) compared to patients with ICI\u2010PsO only (39.7 weeks), although the majority of both groups had grade II severity. Among the 13 patients with preexisting disease and no exposure to apremilast before ICI therapy, all patients in the ICI\u2010PsO\u2013only group (100%) responded to apremilast with either a complete or partial response, whereas only 57% of patients in the ICI\u2010PsA group had complete or partial response. Twenty\u2010nine percent of patients in the entire cohort had to discontinue apremilast due to intolerability. Thirty\u2010eight percent of the entire cohort had progression of cancer or death at last follow\u2010up after being on apremilast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the potential benefit of apremilast for the treatment of ICI\u2010PsO, both de novo and PsO flare, with less of an apparent benefit for ICI\u2010PsA. Thirty percent of patients in the whole group had to discontinue apremilast due to intolerance. Apremilast may be an attractive therapeutic option for either condition given that it is not immunosuppressive, but further prospective observational studies with larger patient numbers are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.25604","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T08:18:08Z","timestamp":1752481088000},"page":"1487-1492","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis"],"prefix":"10.1002","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8799-9309","authenticated-orcid":false,"given":"Nilasha","family":"Ghosh","sequence":"first","affiliation":[{"name":"Hospital for Special Surgery and Weill Cornell Medical College  New York City New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankti","family":"Reid","sequence":"additional","affiliation":[{"name":"University of Chicago  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"McCarter","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Ge","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery  New York City New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-8351","authenticated-orcid":false,"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery and Weill Cornell Medical College  New York City New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04665-7"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105795"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001370"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223885"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11181"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14830"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdrv.2024.10.007"},{"key":"e_1_2_5_13_1","unstructured":"CTCAE and Adverse Event Reporting.National Cancer Institute Division of Cancer Treatment & Diagnosis. Accessed August 22 2025.https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez297"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00783-7"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25604","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.25604","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:02:43Z","timestamp":1773925363000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/acr.25604"],"URL":"https:\/\/doi.org\/10.1002\/acr.25604","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"2025-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}